SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77041.67
227.73 (-0.29%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
31	Suraksha Diagnostic Ltd.	Q V PT	1,482 Small Cap	284.25 (-0.14%)	44.53	6.24	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
32	Gufic Biosciences Ltd.	Q V PT	2,932 Small Cap	289.95 (-0.82%)	58	4.55	16.69	24.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
33	Fermenta Biotech Ltd.	Q V PT	881 Small Cap	298 (-0.45%)	12.23	2.13	7.46	0.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
34	Bajaj Healthcare Ltd.	Q V PT	1,105 Small Cap	323.45 (-1.46%)	21.12	2.19	5.76	2.91	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
35	Advanced Enzyme Technologies Ltd.	Q V PT	3,960 Small Cap	359.25 (1.54%)	32.85	5.79	7.28	11.87	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
36	Biocon Ltd.	Q V PT	58,418 Mid Cap	367 (1.83%)	7894.26	3.64	2.44	-9.71	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
37	FDC Ltd.	Q V PT	6,057 Small Cap	368.05 (-1.06%)	26.67	2.46	9.23	1.32	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
38	Gujarat Themis Biosyn Ltd.	Q V+ PT	4,064 Small Cap	369.75 (-0.86%)	85.04	14.68	12.12	15.55	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
39	Panacea Biotec Ltd.	Q V+ PT	2,280 Small Cap	371.60 (-0.16%)	N/A	8.02	-8.75	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
40	Unichem Laboratories Ltd.	Q V PT	2,714 Small Cap	381.95 (-0.93%)	12.04	1.03	13.92	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
41	Aarti Drugs Ltd.	Q V+ PT	3,604 Small Cap	390.55 (-1.10%)	17.79	2.39	5.74	4.42	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
42	SMS Pharmaceuticals Ltd.	Q V+ PT	3,796 Small Cap	401.05 (-1.06%)	43.48	4.84	13.70	14.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
43	Indraprastha Medical Corporation Ltd.	Q V+ PT	3,784 Small Cap	415.55 (0.68%)	20.68	5.41	10.30	29.46	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
44	Thyrocare Technologies Ltd.	Q V PT	6,703 Small Cap	430.20 (2.15%)	48.7	10.03	9.62	-1.08	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
45	Shilpa Medicare Ltd.	Q V PT	8,189 Small Cap	431.20 (2.99%)	54.58	3.29	7.22	-12.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
46	Syngene International Ltd.	Q V+ PT	19,275 Small Cap	451.70 (-5.40%)	63.22	4.1	10.89	4.48	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
47	Dr. Agarwals Health Care Ltd.	Q V PT	14,363 Small Cap	455 (0.41%)	113.95	7.27	26.38	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
48	Cohance Lifesciences Ltd.	Q V+ PT	17,979 Small Cap	459.25 (-2.28%)	89.14	4.71	7.51	-3.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
49	Blue Jet Healthcare Ltd.	Q V PT	8,263 Small Cap	486.70 (2.17%)	28.15	6.38	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
50	Vimta Labs Ltd.	Q V+ PT	2,129 Small Cap	490.70 (2.94%)	28.5	4.91	13.74	62.65	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
51	Shree Ganesh Remedies Ltd.	Q V PT	625 Small Cap	493.85 (1.36%)	34.55	3.99	13.20	20.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
52	Solara Active Pharma Sciences Ltd.	Q V PT	2,497 Small Cap	499.60 (-3.63%)	N/A	2.01	-0.58	-134.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
53	Metropolis Healthcare Ltd.	Q V PT	10,215 Small Cap	507 (2.90%)	60.71	6.78	9.22	2.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
54	Nephrocare Health Services Ltd.	Q V+ PT	5,493 Small Cap	542.35 (-0.92%)	160.43	9.94	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
55	Indegene Ltd.	Q V+ PT	12,869 Small Cap	548 (2.58%)	32.08	4.1	34.59	31.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
56	Akums Drugs & Pharmaceuticals Ltd.	Q V PT	8,802 Small Cap	552.10 (-1.28%)	70.97	3.66	12.22	23.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
57	Krsnaa Diagnostics Ltd.	Q V PT	1,914 Small Cap	586.65 (-0.58%)	23.81	2.04	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
58	Healthcare Global Enterprises Ltd.	Q V+ PT	9,043 Small Cap	610.40 (0.78%)	389.79	7.59	13.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
59	Orchid Pharma Ltd.	Q V PT	3,190 Small Cap	627 (-0.30%)	75.14	2.38	13.89	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
60	Lincoln Pharmaceuticals Ltd.	Q V PT	1,284 Small Cap	672.35 (4.85%)	14.62	1.73	10.63	11.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Wockhardt	1,545.45	8.41%
Anuh Pharma	84.61	6.16%
Lincoln Pharma	672.35	4.85%
Shilpa Medicare	431.20	2.99%
Vimta Labs	490.70	2.94%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Syngene Internation.	451.70	-5.40%
RPG Life Sciences	2,319.25	-4.31%
Solara Active Pharma	499.60	-3.63%
Aarti Pharmalabs	778.25	-3.41%
Tarsons Products	216.75	-3.04%

News about Top Pharma Companies in India

May, 2026

SMS Pharmaceuticals informs about newspaper publication

SMS Pharmaceuticals has enclosed copies of the newspaper advertisements published today in the the Financial Express (English), and in Nava Telangana (Telugu), informing about the Investor Education and Protection Fund Authority’s (IEPFA) ‘Second 100-Days CampaignSaksham Niveshak’. This information is also being uploaded on the Company’s website at www.smspharma.com

The above information is a part of company’s filings submitted to BSE.

May, 2026

Bajaj Healthcare submits board meeting intimation

Bajaj Healthcare has informed that the meeting of the Board of Directors of the Company is scheduled on 08/05/2026, to consider and approve Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026; and recommend Final Dividend on Equity Shares if any, for the Financial Year 2025-26 subject to the approval of Shareholders of the Company at the ensuing Annual General Meeting of the Company.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Panacea Biotec informs about disclosure

Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations), Panacea Biotec has informed that the Income Tax Appellate Tribunal (ITAT) vide its Order dated April 29, 2026, allowed the appeal filed by the Company and set aside the Order dated August 14, 2025 of Commissioner of Income Tax (Appeals) (CIT(A)) arising out of Rectified Assessment Order dated October 10, 2023 passed earlier by Assessing Officer u/s 143(3) read with section 154 of the Income Tax Act, 1961 (Act). As per the aforesaid Rectified Assessment Order dated October 10, 2023, the Assessing Officer raised a demand of ?9.16 Crore for Assessment Year 2020-21 on account of addition of ?3.44 Crore under Section 14A of the Act read with Rule 8D of the Income Tax Rules, 1962. The aforesaid ITAT Order effectively results in deletion of the said disallowances of expenses as well as cancellation of demand of ?9.16 Crore previously raised by Assessing Officer for the Assessment Year 2020- 21. The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations, are annexed as Annexure A.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Indegene gains even after reporting 32% fall in Q4 consolidated net profit

The total consolidated income of the company increased by 29.83% at Rs 1014.20 crore for Q4FY26

Apr, 2026

Indegene reports 32% fall in Q4 consolidated net profit

The total consolidated income of the company increased by 29.83% at Rs 1014.20 crore for Q4FY26

Apr, 2026

USFDA completes Pre-License inspection at Biocon’s biosimilars site

At the conclusion of the inspection, the USFDA issued a Form 483 with five observations

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	237 Crore
2	Syncom Formulations (India) Ltd.	1,296 Crore
3	Sigachi Industries Ltd.	773 Crore
4	Fischer Medical Ventures Ltd.	2,487 Crore
5	Morepen Laboratories Ltd.	2,298 Crore
6	Anuh Pharma Ltd.	799 Crore
7	KMC Speciality Hospitals (India) Ltd.	1,402 Crore
8	IOL Chemicals And Pharmaceuticals Ltd.	2,787 Crore
9	Themis Medicare Ltd.	914 Crore
10	Gujarat Kidney And Super Speciality Ltd.	992 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,338	54,030	35.45	12.32	24.78	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,267	1,43,909	63.34	15.84	35.80	26.68
Ajanta Pharma Ltd. (S)	Very Good	2,887	36,283	35.76	7.91	24.47	24.45
Lupin Ltd. (M)	Somewhat Good	2,342	1,07,489	23.14	5.16	13.79	20.83
Zydus Lifesciences Ltd. (M)	Very Good	909	90,727	18.37	3.45	11.47	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,166	62,974	88.04
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,415	67,519	73.93
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,086	33,373	31.79
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,267	1,43,909	30.58
Gland Pharma Ltd. (S)	Very Good	1,770	29,941	29.37
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,086	33,373	45.88	8.55	28.97	17.81
Mankind Pharma Ltd. (M)	Very Good	2,275	93,324	54.78	5.85	32.99	14.65
Laurus Labs Ltd. (M)	Very Good	1,166	62,974	70.85	11.88	35.61	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,274	1,07,500	19.31	2.89	11.61	13.26
Ajanta Pharma Ltd. (S)	Very Good	2,887	36,283	35.76	7.91	24.47	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	909	90,727	18.37	3.45	11.47	30.57
Cipla Ltd. (L)	Very Good	1,325	1,07,827	23.72	3.21	14.30	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,821	4,37,663	40.10	5.39	21.92	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,274	1,07,500	19.31	2.89	11.61	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,086	33,373	45.88	8.55	28.97	19.45

You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

SMS Pharmaceuticals informs about newspaper publication

Bajaj Healthcare submits board meeting intimation

Panacea Biotec informs about disclosure

Indegene gains even after reporting 32% fall in Q4 consolidated net profit

Indegene reports 32% fall in Q4 consolidated net profit

USFDA completes Pre-License inspection at Biocon’s biosimilars site

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.